Digestive Diseases Branch, National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
Liver Diseases Branch, National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
J Viral Hepat. 2020 Apr;27(4):428-436. doi: 10.1111/jvh.13235. Epub 2019 Dec 9.
Noninvasive detection of cirrhosis via vibration-controlled transient elastography (VCTE) has revolutionized the management of chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. However, VCTE has not been studied in chronic hepatitis D virus (HDV) infection and accuracy remains in question due to the significant hepatic inflammation associated with this infection. Consecutive HBV, HCV and HDV patients who underwent VCTE (2006-2019) were evaluated. Diagnosis of cirrhosis was made via liver biopsy or clinical findings. VCTE was compared with other noninvasive serum fibrosis tests using AUROC curves. The performance of VCTE in HBV/HCV/HDV was also compared. We evaluated 319 patients (HBV-112; HCV-132; HDV-75), 278(87%) patients had histology for evaluation. HDV patients had evidence of higher hepatic inflammation as evidence by aspartate aminotransferase, alanine aminotransferase and histology activity index. Cirrhotic HDV patients had higher mean liver stiffness measurements compared with noncirrhotic patients (29.0 vs 8.3 kPa, P < .0001). VCTE demonstrated excellent diagnostic accuracy for the detection of cirrhosis with an AUROC of 0.90 compared with APRI (0.83), FIB-4 (0.88), AAR (0.73) and RPR (0.85). Performance of VCTE in HDV was comparable with HBV (0.93) and HCV (0.94). At the optimized cut-off value of ≥14.0 kPa for determining cirrhosis in HDV, VCTE had a sensitivity of 0.78, specificity of 0.86, NPV of 0.93 and PPV of 0.64. Hence, VCTE is a useful noninvasive test in HDV for determining cirrhosis despite the presence of significant hepatic inflammation.
经振动控制瞬时弹性成像(VCTE)的非侵入性肝硬化检测方法已经彻底改变了慢性乙型肝炎病毒(HBV)和丙型肝炎病毒(HCV)感染的管理方式。然而,由于与这种感染相关的显著肝脏炎症,VCTE 尚未在慢性丁型肝炎病毒(HDV)感染中进行研究,其准确性仍存在疑问。我们评估了 2006 年至 2019 年期间接受 VCTE 检查的连续 HBV、HCV 和 HDV 患者。通过肝活检或临床发现诊断肝硬化。使用 AUROC 曲线比较 VCTE 与其他非侵入性血清纤维化检测方法的准确性。还比较了 VCTE 在 HBV/HCV/HDV 中的性能。我们评估了 319 名患者(HBV-112;HCV-132;HDV-75),其中 278 名(87%)患者有组织学检查结果。HDV 患者的天门冬氨酸转氨酶、丙氨酸转氨酶和组织学活动指数均提示肝脏炎症更为明显。与非肝硬化患者相比,肝硬化 HDV 患者的平均肝硬度测量值更高(29.0 与 8.3kPa,P<.0001)。VCTE 检测肝硬化的 AUROC 为 0.90,与 APRI(0.83)、FIB-4(0.88)、AAR(0.73)和 RPR(0.85)相比,具有优异的诊断准确性。VCTE 在 HDV 中的性能与 HBV(0.93)和 HCV(0.94)相当。在 HDV 中确定肝硬化的最佳截断值≥14.0kPa 时,VCTE 的敏感性为 0.78,特异性为 0.86,阴性预测值为 0.93,阳性预测值为 0.64。因此,尽管存在显著的肝脏炎症,VCTE 仍是一种用于确定 HDV 肝硬化的有用的非侵入性检测方法。